HRP20161318T1 - Farmaceutski pripravak koji sadržava fosfolipid - Google Patents
Farmaceutski pripravak koji sadržava fosfolipid Download PDFInfo
- Publication number
- HRP20161318T1 HRP20161318T1 HRP20161318TT HRP20161318T HRP20161318T1 HR P20161318 T1 HRP20161318 T1 HR P20161318T1 HR P20161318T T HRP20161318T T HR P20161318TT HR P20161318 T HRP20161318 T HR P20161318T HR P20161318 T1 HRP20161318 T1 HR P20161318T1
- Authority
- HR
- Croatia
- Prior art keywords
- concentration
- phospholipid
- pharmaceutical preparation
- mass
- weight
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title claims 28
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 21
- 238000002360 preparation method Methods 0.000 claims 14
- 239000004480 active ingredient Substances 0.000 claims 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 10
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 6
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- -1 dermatotics Substances 0.000 claims 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 4
- 229960001259 diclofenac Drugs 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 3
- 229960000991 ketoprofen Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 244000068988 Glycine max Species 0.000 claims 2
- 241000208818 Helianthus Species 0.000 claims 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 235000013339 cereals Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 239000000419 plant extract Substances 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 229940043375 1,5-pentanediol Drugs 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- JJDDPDHSLLONIF-UHFFFAOYSA-N C=C.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound C=C.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O JJDDPDHSLLONIF-UHFFFAOYSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 102000039471 Small Nuclear RNA Human genes 0.000 claims 1
- 108020004688 Small Nuclear RNA Proteins 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000003555 analeptic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000001857 anti-mycotic effect Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002543 antimycotic Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000001989 choleretic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000000645 desinfectant Substances 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000000686 essence Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 229940051250 hexylene glycol Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003049 inorganic solvent Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 230000001790 virustatic effect Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (29)
1. Farmaceutski pripravak za primjenu kod ljudi i životinja, koji sadržava najmanje jedan aktivni sastojak za lokalnu primjenu, koji djeluje sistemski i/ili lokalno, i najmanje jednim fosfolipidom, koji sadržava fosfatidilkolin u koncentraciji od najmanje 60% težinskih udjela, u odnosu na fosfolipid, pri čemu pripravak ima tekuću konzistenciju tako da se može raspršiti u obliku kapljica, naznačen time, da pripravak sadržava takav fosfolipid koji poboljšava prijenos aktivnog sastojka kroz staničnu membranu i koji dodatno sadržava ulje u koncentraciji između 2% težinskog udjela i 4,8 % težinskog udjela uz najmanje 60 % masenog udjela fosfatidilkolina.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je fosfolipid smjesa fosfolipida i koja osim fosfatidilkolina sadržava lizofosfatidilkolin, fosfatidnu kiselinu, fosfatidiletanolamin i / ili fosfatidilinozitol.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je fosfolipid fosfolipid koji je izoliran iz biljnih komponenti, naročito) iz sjemena žitarica i/ili sjemena bogatog uljem, a poželjno je od soje ili suncokreta.
4. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da je koncentracija fosfatidilkolina u fosfolipidu najmanje 75 % masenog udjela.
5. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da je koncentracija fosfatidilkolina u fosfolipidu 78,1 % +/- 3 % masenog udjela.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time, da fosfolipid sadržava lizofosfatidilkolin u koncentraciji manjoj od 5,6 % masenog udjela, fosfatidiletanolamina u koncentraciji manjoj od 5,2 % masenog udjela i fosfatidne kiseline u koncentraciji manjoj od 2,9 % masenog udjela.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time, da fosfolipid sadržava lizofosfatidilkolin u koncentraciji između 5,5 % i 1,5 % masenog udjela, fosfatidiletanolamin u koncentraciji između 5,1 % i 2,3 % masenog udjela i fosfatidne kiseline u koncentraciji između 2,5 % i 0,9 % masenog udjela.
8. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da pripravak sadržava neko anorgansko ili organsko otapalo.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time, da pripravak sadržava vodu i/ili alkohol, osobito etanol, izopropanol, jedan ili više glikola i/ili glicerola kao otapalo.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time, da pripravak sadržava propilen glikol, butilen glikol, pentilen glikol i/ili heksilen glikol kao glikol.
11. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da pripravak sadržava smjesu otapala koja sadržava vodu i najmanje jedan alkohol, a poželjno je izopropil alkohol.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time, da koncentracija vode u tekućem pripravku varira između 50 % i 95 % masenog udjela, poželjno između 55 % i 75 % masenog udjela, a koncentraciju najmanje jednog alkohola varira između 5 % i 50 % masenog udjela, poželjno između 8 % i 25 % masenog udjela.
13. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da je najmanje jedan aktivni sastojak odabran iz grupe koja uključuje lokalne anestetike, sredstva protiv alergije, dermatike, aktivne tvari protiv infekcija gripe i prehlade, aktivne tvari za liječenje neuropatije, aktivne tvari za liječenje poremećene cirkulacije, kemoterapeutike, kinin, antimikotike, antibiotike, talidomid, serotonin, eikozanoid, analgetike, sredstva protiv grčeva, nesteroidne antireumatike, leukotrien, inhibitore leukotriena, androgene, antiandrogene, kortiko steroide, antagoniste receptora opijata, antikoagulantske tvari, inhibitore agregacije trombocita, antagoniste histamina, peptide i proteine s regulatornim i enzimatskim djelovanjem, nukleinske kiseline (jednostruke i dvostruke DNK, jednostruke i dvostruke RNK, snRNK, DNK oligonukletide, RNK oligonukletide) i oligopeptide, antipruritike, antidijabetike, prostaglandine, inhibitore sinteze prostaglandina, tvari s antivirusnim ili virostatskim djelovanjem, tvari s antimikrobnim djelovanjem, aktivne sastojke protiv priona, imunosupresive, hormone, aktivne tvari za liječenje bradavica ili rana, posebno kroničnih rana, vitamine, biljne ekstrakte ili esencije biljnih ekstrakata, psihoaktivne supstance, aktivne sastojke koji utječu na spavanje, analeptike, anestetike, mišićne relaksanse, antiepileptike, agense protiv Parkinsonove bolesti, antiemetike, antiparazitike, aktivne sastojke protiv gangliona, simpatički-aktivne sastojke, parasimpatički-aktivne sastojke, antibakterijske lijekove, antagoniste kalcija, kardiovaskularna sredstva, antiastmatike, antitusike, sredstva za iskašljavanje, koleretike, dezinficijense, elemente u tragovima, antiinfektivne agense, citostatike, antimetabolite, antagoniste hormona, imunomodulatore kao i derivate i soli navedenih aktivnih sastojaka.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time, da je analgetik odabran iz skupine koju sačinjavaju diklofenak, ketoprofen i ibuprofen.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačen time, da je analgetik u pripravku diklofenak, a diklofenak je prisutan u pripravku u obliku alkalne soli, osobito u obliku natrijeve soli.
16. Farmaceutski pripravak u skladu s jednim od patentnih zahtjeva 13 do 15, naznačen time, da je diklofenak prisutan u pripravku u koncentraciji između 0,1% i 10% masenog udjela, poželjno u koncentraciji između 1% i 6% masenog udjela.
17. Farmaceutski pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačen time, da pripravak sadržava ketoprofen, koji je najmanje jedan aktivni sastojak, te da koncentracija ketoprofena u pripravku varira između 5 % i 15 % masenog udjela, poželjno između 8 % i 12 % masenog udjela.
18. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da pripravak sadržava najmanje jedan fosfolipid u koncentraciji između 0,5 % i 20 % masenog udjela, poželjno u koncentraciji od 5 % i 13 % masenog udjela.
19. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da pripravak nadalje sadržava sredstvo za tvorbu kompleksa, osobito etilen tetraoctenu kiselinu, najmanje jedno pufersko sredstvo, osobito fosfatni pufer, najmanje jedan antioksidans, posebno palmitoil askorbinska kiselina, najmanje jedan parfem i/ili aromu.
20. Farmaceutski pripravak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da ulje koje se nalazi u najmanje jednom fosfolipidu sadržava slobodne masne kiseline, sterole, monogliceride i digliceride, trigliceride, tokoferol i/ili estere masnih kiselina.
21. Uporaba najmanje jednog fosfolipida, kao pojačivača prožimanja i/ili prodiranja u farmaceutskom pripravku u skladu s jednim od prethodnih patentnih zahtjeva, naznačena time, da fosfolid sadržava fosfatidilkolin u koncentraciji od najmanje 60 % masenog udjela, u odnosu na fosfolipid i da fosfolipid osim najmanje 60 % fosfatidilholina nadalje sadržava ulje u koncentraciji između 4,8 % i 2 % masenog udjela.
22. Uporaba u skladu s patentnim zahtjevom 21, naznačena time, da fosfolipid nadalje sadržava ulje u koncentraciji između 4 % i 2 % masenog udjela.
23. Uporaba u skladu s patentnim zahtjevom 21 ili 22, naznačena time, da je fosfolipid smjesa fosfolipida i da osim fosfatidilkolina dodatno sadržava lizofosfatidilkolin, fosfatidnu kiselinu, fosfatidiletanolamin i/ili fosfatidilinozitol.
24. Uporaba u skladu s jednim od patentnih zahtjeva 21 do 23, naznačena time, da je fosfolipid fosfolipida koji je izoliran iz biljnih komponenti, naročito iz sjemenki žitarica i/ili sjemenki bogatog uljem poželjno od soje ili suncokreta.
25. Uporaba u skladu s jednim od patentnih zahtjeva 21 do 24, naznačena time, da fosfolipid ima koncentraciju fosfatidilkolina od najmanje 75 % masenog udjela.
26. Uporaba u skladu s patentnim zahtjevom 25, naznačena time, da fosfolipid ima koncentraciju fosfatidilkolina 78,1% +/- 3% težinskog udjela.
27. Uporaba u skladu s jednim od patentnih zahtjeva 21 do 26, naznačena time, da fosfolipid ima koncentraciju lizofosfatidilkolina manju od 5,6 % masenog udjela, fosfatidiletanolamina manju od 5,2 % masenog udjela i fosfatidne kiseline manju od 2,9 % masenog udjela.
28. Uporaba u skladu s jednim od patentnih zahtjeva 21 do 27, naznačena time, da fosfolipid sadržava lizofosfatidilkolin u koncentraciji između 5,5 % i 1,5 % masenog udjela, fosfatidiletanolamin u koncentraciji između 5, 1 % i 2,3 % masenog udjela i fosfatidnu kiselinu u koncentraciji između 2,5 % i 0,9 % masenog udjela.
29. Uporaba u skladu s jednim od patentnih zahtjeva 21 do 28, naznačena time, da ulje koje se nalazi u najmanje jednom fosfolipidu sadržava slobodne masne kiseline, sterole, monogliceride i digliceride, trigliceride, tokoferol i/ili masne kiseline.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012009575 | 2012-05-15 | ||
| DE102013004199A DE102013004199A1 (de) | 2012-05-15 | 2013-03-12 | Pharmazeutische Zusammensetzung |
| EP13001361.8A EP2638894B1 (de) | 2012-05-15 | 2013-03-18 | Pharmazeutische Zusammensetzung mit Phospholipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161318T1 true HRP20161318T1 (hr) | 2016-12-16 |
Family
ID=47901750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161318TT HRP20161318T1 (hr) | 2012-05-15 | 2016-10-11 | Farmaceutski pripravak koji sadržava fosfolipid |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2638894B1 (hr) |
| JP (1) | JP2013237669A (hr) |
| BR (1) | BR102013011801B1 (hr) |
| CA (1) | CA2815477C (hr) |
| CY (1) | CY1118727T1 (hr) |
| DE (1) | DE102013004199A1 (hr) |
| DK (1) | DK2638894T3 (hr) |
| ES (1) | ES2606031T3 (hr) |
| HR (1) | HRP20161318T1 (hr) |
| HU (1) | HUE029793T2 (hr) |
| LT (1) | LT2638894T (hr) |
| MX (1) | MX342069B (hr) |
| PL (1) | PL2638894T3 (hr) |
| PT (1) | PT2638894T (hr) |
| RS (1) | RS55291B1 (hr) |
| RU (1) | RU2659943C2 (hr) |
| SI (1) | SI2638894T1 (hr) |
| SM (1) | SMT201600419B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59209542D1 (de) * | 1991-07-05 | 1998-12-03 | Rhone Poulenc Rorer Gmbh | Phospholipidische Zusammensetzung |
| US6113921A (en) * | 1993-03-23 | 2000-09-05 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
| DE4313402A1 (de) * | 1993-04-23 | 1994-10-27 | Hexal Pharma Gmbh | Transdermale Wirkstoffzubereitung |
| EP0746294B1 (en) * | 1993-10-07 | 2004-12-22 | Odontex, Inc. | Absorption enhancers for topical pharmaceutical formulations |
| ATE223202T1 (de) | 1994-09-30 | 2002-09-15 | Mika Pharma Ges Fuer Die Entwi | Pharmazeutische zusammensetzung |
| JP2008514606A (ja) * | 2004-09-24 | 2008-05-08 | リポ ケミカルズ インコーポレイテッド | 局所適用化合物のためのデリバリーシステム |
| RU2532027C2 (ru) * | 2009-07-24 | 2014-10-27 | Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх | Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки |
-
2013
- 2013-03-12 DE DE102013004199A patent/DE102013004199A1/de not_active Ceased
- 2013-03-18 ES ES13001361.8T patent/ES2606031T3/es active Active
- 2013-03-18 SI SI201330401A patent/SI2638894T1/sl unknown
- 2013-03-18 RS RS20160854A patent/RS55291B1/sr unknown
- 2013-03-18 DK DK13001361.8T patent/DK2638894T3/en active
- 2013-03-18 LT LTEP13001361.8T patent/LT2638894T/lt unknown
- 2013-03-18 EP EP13001361.8A patent/EP2638894B1/de active Active
- 2013-03-18 HU HUE13001361A patent/HUE029793T2/en unknown
- 2013-03-18 PL PL13001361T patent/PL2638894T3/pl unknown
- 2013-03-18 PT PT130013618T patent/PT2638894T/pt unknown
- 2013-05-08 JP JP2013098271A patent/JP2013237669A/ja active Pending
- 2013-05-09 CA CA2815477A patent/CA2815477C/en active Active
- 2013-05-10 MX MX2013005306A patent/MX342069B/es active IP Right Grant
- 2013-05-10 RU RU2013121269A patent/RU2659943C2/ru active
- 2013-05-13 BR BR102013011801-0A patent/BR102013011801B1/pt not_active IP Right Cessation
-
2016
- 2016-10-11 HR HRP20161318TT patent/HRP20161318T1/hr unknown
- 2016-11-14 CY CY20161101165T patent/CY1118727T1/el unknown
- 2016-11-18 SM SM201600419T patent/SMT201600419B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS55291B1 (sr) | 2017-03-31 |
| CA2815477A1 (en) | 2013-11-15 |
| HUE029793T2 (en) | 2017-04-28 |
| BR102013011801B1 (pt) | 2022-08-09 |
| EP2638894A1 (de) | 2013-09-18 |
| SMT201600419B (it) | 2017-01-10 |
| JP2013237669A (ja) | 2013-11-28 |
| CA2815477C (en) | 2017-05-02 |
| PL2638894T3 (pl) | 2017-02-28 |
| RU2013121269A (ru) | 2014-11-20 |
| MX2013005306A (es) | 2013-11-26 |
| CY1118727T1 (el) | 2017-07-12 |
| MX342069B (es) | 2016-09-13 |
| LT2638894T (lt) | 2017-02-10 |
| DK2638894T3 (en) | 2016-10-17 |
| SI2638894T1 (sl) | 2017-01-31 |
| DE102013004199A1 (de) | 2013-11-21 |
| RU2659943C2 (ru) | 2018-07-04 |
| ES2606031T3 (es) | 2017-03-17 |
| PT2638894T (pt) | 2016-12-13 |
| EP2638894B1 (de) | 2016-09-14 |
| BR102013011801A2 (pt) | 2015-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250865B2 (ja) | 固溶体組成物および心血管疾患における使用 | |
| HRP20170376T1 (hr) | Postupak za izradu tekućeg pripravka koji se primjenjuje na kožu u obliku pjene i pripravka koji se može primijeniti lokalno | |
| RU2680801C2 (ru) | Композиции и способы для лечения хронического воспаления и воспалительных заболеваний | |
| RU2635188C2 (ru) | Композиции и способы для лечения хронического воспаления и воспалительных заболеваний | |
| HRP20161720T1 (hr) | Emulzija | |
| JP2013500239A5 (hr) | ||
| JP2013100317A5 (hr) | ||
| HRP20161318T1 (hr) | Farmaceutski pripravak koji sadržava fosfolipid | |
| RU2009136228A (ru) | Фармацевтическая композиция для топического применения | |
| JP2002513749A5 (hr) | ||
| PT1282446E (pt) | Composição farmacêutica e/ou cosmética contendo um organossiloxano e um fodfolípido | |
| CN102858333A (zh) | 呼吸紊乱的治疗 | |
| KR102188840B1 (ko) | 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 | |
| RS54824B1 (sr) | Topikalna formulacija za inhibiciju jak-a | |
| NZ610465A (en) | Clevidipine emulsion formulations containing antimicrobial agents | |
| TW201444553A (zh) | 外用醫藥組成物 | |
| HRP20240058T1 (hr) | Formulacije bedakvilina s dugotrajnim djelovanjem | |
| DE102009012465A1 (de) | Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung | |
| HRP20210865T1 (hr) | Ulje-u-vodi nanoemulzijski pripravak klobetazola | |
| US20160374970A1 (en) | Pharmaceutical composition | |
| Patel et al. | An inclusive review on novel drug delivery strategies for an effectual delivery of bio-active drug molecules in the treatment of acne | |
| Pate et al. | AN INCLUSIVE REVIEW ON NOVEL DRUG DELIVERY STRATEGIES FOR AN EFFECTUAL DELIVERY OF BIO-ACTIVE DRUG MOLECULES IN THE TREATMENT OF ACNE. | |
| WO2019063863A1 (es) | Método para la obtención de microcápsulas, microcápsulas obtenidas mediante el mismo, y composiciones nutracéuticas o farmacéuticas que comprenden dichas microcápsulas | |
| JP2005029576A (ja) | 温感作用を持った皮膚用塗布剤 | |
| TH8219A3 (th) | ผลิตภัณฑ์น้ำมันแอนโนนา (Annona oil) ชนิดกึ่งเหลว (semi-solid dosage form) เพื่อใช้กำจัดเหา |